The prevalence of chronic lymphocytic leukemia (CLL) in the United States is on the rise. To enhance the delivery of individualized treatment, clinicians must be familiar with the efficacy and safety of current treatment options as well as molecular features of CLL and patient characteristics that drive treatment selection. In this activity, an expert from Harvard Medical School reviews clinical data and national guidelines for individualizing treatment of patients with newly diagnosed or relapsed/refractory CLL, and discusses strategies to manage adverse events and improve treatment compliance.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Analyze the efficacy and safety of treatment options as well as molecular features of CLL and patient characteristics/preferences to aid in the successful delivery of individualized therapy to patients with newly diagnosed and relapsed/refractory CLL
- Consider the optimal treatment for patients with newly diagnosed and relapsed/refractory CLL based on available clinical data, guidelines, and expert recommendations
- Develop team-based strategies to address challenges to optimal treatment, including the identification and management of adverse events, to ensure treatment compliance as well as improved clinical outcomes and quality of life
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
The maximum number of hours awarded for this activity is 1.00 contact hours, which includes 1.00 hours of pharmacology credit.
AAPA Credit Designation
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2021. PAs should only claim credit commensurate with the extent of their participation.
This program was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer; Celgene Corporation; Exelixis; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; Sanofi Genzyme; Seattle Genetics; and Verastem Oncology.
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Clinical Care Options, LLC, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Clinical Care Options, LLC are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Sandy: speakers bureau: AstraZeneca, Merck, Takeda.
Dr Soumerai: consultant: AbbVie, AstraZeneca, Verastem; grant/research support: BeiGene, BostonGene, Roche/Genentech, TG Therapeutics.
None of the members of the Clinical Care Options, LLC staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Watch the eCourse in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
Release date: August 15, 2020
Expiration date: August 14, 2021
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97520OPCE-7I